HC Wainwright & Co. Maintains Buy on IO Biotech, Raises Price Target to $12
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Emily Bodnar maintains a Buy rating on IO Biotech (NASDAQ:IOBT) and raises the price target from $8 to $12.
May 15, 2024 | 3:39 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Emily Bodnar maintains a Buy rating on IO Biotech and raises the price target from $8 to $12.
The raised price target from $8 to $12 and maintained Buy rating by a reputable analyst is likely to positively impact investor sentiment and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100